Inclusion Criteria:

          1. Histopathologic documentation of melanoma, synovial sarcoma or mixed round cell
             liposarcoma concurrent with the diagnosis of metastatic disease.

          2. Tumor expression of NY-ESO-1 (2+ staining or > 25%) by IHC.

          3. Male or female subjects ≥18 years of age.

          4. Expression of HLA-DPB1*0401

          5. Eastern Cooperative Oncology Group (ECOG)/ Zubrod performance status of '0-1' .

          6. Women of childbearing potential (WOCBP) must be using an adequate method of
             contraception to avoid pregnancy throughout the study in such a manner that the risk
             of pregnancy is minimized. Suggested precautions should be used to minimize the risk
             or pregnancy for at least 1 month before start of therapy, and while women are on
             study for up to 3 months after T cell infusion, and at least 8 weeks after the study
             drug is stopped. WOCBP include any female who has experienced menarche and who has not
             undergone successful surgical sterilization (hysterectomy, bilateral tubal ligation or
             bilateral oophorectomy) or is not postmenopausal

          7. Men must be willing and able to use an acceptable method of birth control, for at
             least 3 months after completion of the study, if their sexual partners are WOCBP.

          8. Willing and able to give informed consent.

          9. Adequate venous access - consider peripherally inserted central venous catheter (PICC)
             or central line

         10. Bi-dimensionally measurable disease by palpation on clinical exam, or radiographic
             imaging (X-ray or CT scan)

         11. At least 4 weeks must have elapsed since the last chemotherapy, immunotherapy,
             radiotherapy, or major surgery.

         12. At least 6 weeks must have elapsed since the last nitrosoureas, mitomycin C and
             liposomal doxorubicin

         13. Toxicity related to prior therapy must either have returned to < or equal to grade 1,
             baseline, or been deemed irreversible

        Exclusion Criteria:

          1. Patients with active infections or oral temperature > 38.2 C within 71 hours of
             Leukapheresis. The procedure may be deferred.

          2. Patients with Hct <30%, white blood count (WBC) <2500/uL and platelets <50,000
             immediately prior to Leukapheresis. The procedure may be deferred.

          3. Any other malignancy from which the patient has been disease-free for less than 5
             years, with the exception of adequately treated and cured basal or squamous cell skin
             cancer, superficial bladder cancer, carcinoma in situ of the cervix.

          4. Complete blood count (CBC) and Chemistry profile prior to cyclophosphamide and T cell
             infusions: WBC < 2000/uL Hct < 24% or Hb < 8 g/dL absolute neutrophil count (ANC) <
             1000 Platelets < 50,000 Creatinine > 3.0 x ULN AST/ALT > 2.5 x ULN Bilirubin > 3 x ULN

          5. Pregnant women, nursing mothers, men or women of reproductive ability who are
             unwilling to use effective contraception. Women of childbearing potential with a
             positive pregnancy test within 3 days prior to entry.

          6. Clinically significant pulmonary dysfunction, as determined by medical history and
             physical exam. Patients so identified will undergo pulmonary functions testing and
             those with FEV1 < 2.0 L or DLco (corr for Hgb) < 75% will be excluded.

          7. Significant cardiovascular abnormalities as defined by any one of the following:
             Congestive heart failure, Clinically significant hypotension, Symptoms of coronary
             artery disease, Presence of cardiac arrhythmias on EKG requiring drug therapy,Ejection
             fraction < 50 % (echocardiogram or MUGA).

          8. Active and untreated central nervous system (CNS) metastasis (including metastasis
             identified during screening MRI or contrast CT).

          9. Autoimmune disease: Patients with a history of Inflammatory Bowel Disease are excluded
             from this study, as are patients with a history of autoimmune disease (e.g. Systemic
             Lupus Erythematosus, vasculitis, infiltrating lung disease) whose possible progression
             during treatment would be considered by the Investigator to be unacceptable.

         10. Any underlying medical or psychiatric condition, which in the opinion of the
             Investigator, will make the administration of study drug hazardous or obscure the
             interpretation of adverse events, such as a condition associated with frequent
             diarrhea.

         11. Positive screening tests for HIV, Hep B, and Hep C. If positive results are not
             indicative of true active or chronic infection, the patient can be treated.

         12. Steroids are not permitted 3 days prior to T cell infusion and concurrently during
             therapy.

         13. Any non-oncology vaccine therapy used for the prevention of infectious disease within
             1 month before or after any ipilimumab dose.

         14. No prisoners or children will be enrolled on this study